Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Prokarium Receives £0.4m Grant to Develop Next Generation Vaccines

Published: Tuesday, March 12, 2013
Last Updated: Monday, March 11, 2013
Bookmark and Share
Grant will allow Prokarium to complete preclinical work on Typhetec®.

A consortium comprising vaccine developer Prokarium Ltd and the University of Birmingham’s Institute of Microbiology and Infection has received an award for ‘advancing the industrial application of synthetic biology’.

The £0.4m grant from the Technology Strategy Board (TSB), the UK’s innovation agency, and the Biotechnology and Biological Sciences Research Council (BBSRC) has been earmarked to help fund the development of Prokarium’s Vaxonella® oral vaccine delivery platform as well as two specific vaccine candidates.

Prokarium, a biotechnology start-up company based in Keele, Staffordshire and London, UK, develops cutting-edge genetic technologies to engineer immune-cell-targeting bacteria that express vaccines from within the body, creating the next generation of safe, affordable, oral vaccines.

The grant will allow Prokarium to complete preclinical work on its first pipeline product Typhetec®, a dual oral vaccine against typhoid and ETEC, a major cause of diarrhoea.

In addition, this grant will enable R&D to commence on a novel vaccine against Clostridium difficile, a major cause of colitis in the elderly.

Currently there are no vaccines against ETEC, a bacterium responsible for between 300,000 and 500,000 deaths annually, including children in developing countries.

In addition, every year more than 10 million travellers contract diarrhoea caused by ETEC, which costs €200m annually in medical resources within the EU, and accounts for €450m in lost productivity.

Similarly, there is no vaccine against C. difficile, responsible for approximately 900,000 cases of colitis a year across Europe and North America, with an estimated cost of care burden of over $7 billion.

With this funding from the TSB and BBSRC, Prokarium and the University of Birmingham will be able to test candidates that have the potential to be developed into oral vaccines for both the developed and emerging markets.

Carl-Johan Spak, CEO of Prokarium, said: “We are very pleased that the TSB and BBSRC awarded our consortium this funding, which will not only bring us closer to creating the next generation of oral vaccines against two very important diseases, but also recognizes Prokarium as an innovative synthetic biology company.”

Prof Ian Henderson, University of Birmingham adds: "Prokarium's Vaxonella platform will revolutionize the way we protect people from infectious and non-infectious disease. I am excited by the opportunity to assist Prokarium in the development of an ETEC vaccine based on Vaxonella. Success in this important endeavour will give the gift of life to millions of children who would otherwise suffer or die from this devastating disease".


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Tuesday, August 04, 2015
Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions
Prokarium to combine Typhella™ and spi-VEC™ with its genetic and formulation technologies to form Vaxonella™.
Tuesday, July 10, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!